LAPULEUCEL-T

Lapuleucel-T, an investigational Active Cellular Immunotherapy also known as NEUVENGE™, has completed two Phase 1 Phase 1 Clinical TrialThe first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase 1 trials usually include only a small number of patients who have not been helped by other treatments.Closeclinical trials for the treatment of patients with breast, ovarian and colorectal solid tumors expressing HER2/neu. Lapuleucel-T targets the HER2/neu antigen AntigenA substance that causes the body's immune system to react. This reaction often involves production of antibodies. For example, the immune system's response to antigens that are part of bacteria and viruses helps people resist infections. Cancer cells have certain antigens that can be found by laboratory tests. They are important in cancer diagnosis and in watching response to treatment. Other cancer cell antigens play a role in immune reactions that may help the body's resistance against cancer. Closeand utilizes the same proprietary antigen-engineering technology as sipuleucel-T, which is in late-stage clinical development. Researchers presented encouraging results from two Phase 1 studies of lapuleucel-T in metastatic breast cancer CancerCancer develops when cells in the body begin to grow out of control. Normal cells grow, divide, and die. Instead of dying, cancer cells continue to grow and form new abnormal cells. Cancer cells often travel to other body parts where they grow and replace normal tissue. This spreading process is called metastasis. When cancer spreads or metastasizes, it is still named after the part of the body where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, not bone cancer. Some cancers, such as blood cancers, do not form a tumor. Not all tumors are cancer. A tumor that is not cancer is called benign and does not grow and spread the way cancer does.Closeat the San Antonio Breast Cancer Symposium. Data were also published in the Journal of Clinical Oncology. We are evaluating future development plans for lapuleucel-T.